Literature DB >> 34158653

Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study).

Ashish Sharma1, Nilesh Kumar2, Nikulaa Parachuri2, Francesco Bandello3, Baruch D Kuppermann4, Anat Loewenstein5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34158653      PMCID： PMC9046192          DOI： 10.1038/s41433-021-01616-9

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   4.456


× No keyword cloud information.
  11 in total

Review 1.  Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective.

Authors:  Ashish Sharma; Nilesh Kumar; Baruch D Kuppermann; Francesco Bandello; Anat Loewenstein
Journal:  Br J Ophthalmol       Date:  2019-07-17       Impact factor: 4.638

2.  Real-Life Clinical Effectiveness of Razumab® (the World's First Biosimilar of Ranibizumab) in Retinal Vein Occlusion: A Subgroup Analysis of the Pooled Retrospective RE-ENACT Study.

Authors:  Shashikant Sharma; Mujtaba A Khan; Alok Chaturvedi
Journal:  Ophthalmologica       Date:  2018-06-26       Impact factor: 3.250

3.  Need of education on biosimilars amongst ophthalmologists: combating the nocebo effect.

Authors:  Ashish Sharma; Nilesh Kumar; Francesco Bandello; Anat Loewenstein; Baruch D Kuppermann
Journal:  Eye (Lond)       Date:  2019-11-29       Impact factor: 3.775

4.  Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data.

Authors:  Ashish Sharma; M Hafeez Faridi; Nilesh Kumar; Nikulaa Parachuri; Rohini Sharma; Baruch D Kuppermann; Francesco Bandello; Anat Loewenstein; Carl D Regillo
Journal:  Eye (Lond)       Date:  2019-12-16       Impact factor: 3.775

5.  Ophthalmic biosimilars: Lessons from India.

Authors:  Ashish Sharma; Nilesh Kumar; Baruch D Kuppermann; Bandello Francesco; Anat Lowenstein
Journal:  Indian J Ophthalmol       Date:  2019-08       Impact factor: 1.848

6.  Biosimilar Ranibizumab (SB11) vs Reference Ranibizumab-Diving Deeper for Safety and Efficacy.

Authors:  Ashish Sharma; Nilesh Kumar; Nikulaa Parachuri
Journal:  JAMA Ophthalmol       Date:  2021-06-01       Impact factor: 7.389

Review 7.  Biosimilars in ophthalmology: "Is there a big change on the horizon?"

Authors:  Ashish Sharma; Prahalad Reddy; Baruch D Kuppermann; Francesco Bandello; Anat Lowenstein
Journal:  Clin Ophthalmol       Date:  2018-10-24

8.  A Multicenter, Retrospective Study (RE-ENACT 2) on Razumab™ (World's First Biosimilar Ranibizumab) in Retinal Vein Occlusion.

Authors:  Shashikant Sharma; Mujtaba Khan; Alok Chaturvedi
Journal:  Ophthalmol Ther       Date:  2020-07-02

9.  A Multicenter, Retrospective Study (RE-ENACT 2) on the Use of Razumab™ (World's First Biosimilar Ranibizumab) in Wet Age-Related Macular Degeneration.

Authors:  Shashikant Sharma; Mujtaba Khan; Alok Chaturvedi
Journal:  Ophthalmol Ther       Date:  2019-12-27

10.  Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.

Authors:  Se Joon Woo; Miroslav Veith; Jan Hamouz; Jan Ernest; Dominik Zalewski; Jan Studnicka; Attila Vajas; Andras Papp; Vogt Gabor; James Luu; Veronika Matuskova; Young Hee Yoon; Tamás Pregun; Taehyung Kim; Donghoon Shin; Neil M Bressler
Journal:  JAMA Ophthalmol       Date:  2021-01-01       Impact factor: 7.389
View more
  2 in total

1.  Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence.

Authors:  Manoj Soman; Indu Nair; Jay U Sheth; Unnikrishnan Nair
Journal:  Ophthalmol Ther       Date:  2022-04-12

2.  Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation.

Authors:  Dhanashree Ratra; Krishnakanta Roy; Sneha Giridhar; Sushant Madaan
Journal:  Ophthalmol Ther       Date:  2021-11-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.